Diana is a Venture Partner at Skylight Investment (a branch of Taiyou Fund from China) and manages a family office that focuses on early-stage biotech and healthcare investments. Taiyou Fund invests in early-stage technology startups affiliated with elite universities and has invested in more than 80 Tsinghua University-affiliated companies; works closely with Zhen Fund, a well-known angel fund in China, and follow on investors include Sequoia Capital China and IDG Capital.
World leading platform tool technology company providing unique solutions for precision genomic diagnostics labs, hospitals, genomic centers, biotech companies, biomedical and agbio researchers. The core long range genomic structural variation analysis technology is based on worldwide exclusive nanoscale fluidic chip technology invented at Princeton University to linearize ultra long DNA molecules for direct imaging , preserving true biomedically relevant de novo native genomic information otherwise lost or hard to get using next generation sequencing. It will transform clinical cytogenetics and genomic medicine.
"Jim Hussey has over 25 years experience as President/CEO or other senior executive roles at several health care and biotech companies including Athenex Pharmaceuticals, Sagent Pharmaceuticals, Ovation Pharmaceuticals, NeoPharm, Physicians Quality Care and Bristol Myers Squibb. Jim has served on several different public and private Boards of Director as well. He is also a biotech angel investor and currently serves as Chairman of the Board of Symbria Health Care and Independent Director at Power Wellness"
"Jim has experience in China having overseen the building and operation of a sterile FDF facility in Chengdu and the planning and building of a sterile FDF facility in Chongqing. Jim has sold products in China and his company won a supply agreement for innovative technology for the Chinese Academy of Sciences."
Last year, I was granted a 10 year unrestricted visa by the Chinese government. Ergo, I like China and like the Chinese people a lot.
I have been very interested in helping expand our firms interest into China.
C-Bridge Capital is a healthcare-dedicated private equity firm that invests in China-related opportunities, including biopharmaceuticals, medical technologies, diagnostics and services.
I in June 2010 received a doctor's degree in medicinal chemistry in China pharmaceutical university, in Sanhome company engaged in new drug research and development for over 7 years, and then work in the business development, responsible for the new project introduction overseas. During the meeting, I hope to contact the frontier information of biomedicine and find some cooperative projects.
As head of corporate investment and licensing / partnering for SPL / Hepalink, interested in exploring opportunity for both ends
Novarcel Group Limited is an investment company focusing on early and growth stage innovative biotechnology and pharmaceutical companies worldwide. Novarcel adopts a global vision to bridge emerging market in China, global financial resources, and therapeutic breakthroughs worldwide. We seek to create and invest in companies whose technology and products can address unmet medical needs and improve quality of life. Novarcel team has extensive industry experiences including R&D, business development, operation, and management in US and China??s pharma, biotech, CRO, and service companies. We aim to be actively involved in helping portfolio companies to grow through various stages and to successfully deliver the breakthrough cures to patients worldwide.
President Gui-Dong Zhu has approved the waiver for this registration along with the other registration under Liping Yang from Guangdong H.S.T. Pharmaceutical Co. Ltd. Thank you.
Mark Tang is a managing director and partner of Good Health Capital New York, a healthcare private equity firm with offices in Asia and New York. Mark has over two decades of experience in the field of biotechnology as an entrepreneur, educator, advisor and investor. He was formerly a research associate at Rockefeller University, an investment banker, a biotech analyst, and a biotech director at Rutgers Business School. Mark attended University of California, NYU and Harvard.
唐马克博士现任纽约Good Health Capital 总监和医药健康风险和私募基金投资人。作为华尔街知名的华人生物技术金融家和企业家，唐博士的从业经验长达二十年。他是中国大陆留学生中最早在华尔街从事生物科技投资银行业务的华人之一。唐博士曾就职于投行摩根斯坦利添惠和潘恩韦伯(联合瑞士银行) 。他作为创始人之一创建了《生物医药投资通信》和2家高科技公司并将其成功兼并退出，在顶尖《自然杂志-生物科技》发表了金融学术评论《实行亚洲生物企业的发展潜力》以及《生物资产风险管理策略》，并撰写了《生物技术投资必读》一书。唐博士就读于加州大学, 纽约大学，和哈佛大学。
Loop Capital is a full-service investment bank, brokerage and advisory firm that provides creative capital solutions for corporate, governmental and institutional entities across the globe. Our reputation for integrity and service - coupled with our track record of success - has allowed us to serve an expanding number of clients from coast to coast. We continue to grow because clients continue to ask us to do more for them, and our uncompromising commitment to excellence means that clients get superior, focused service across our entire platform. Loop Capital is nimble enough to introduce leading-edge technologies enterprise-wide, quickly and efficiently without disrupting client services. We believe in constantly re-investing in the business, seeking continuous improvements that enhance the client experience and client outcomes.
Scott has worked at Abbott and subsequently AbbVie for over twenty years in total. He is currently AbbVie’s Vice President, Scientific Affairs and Head of AbbVie Ventures, where he works closely with the Chief Strategy Officer and executive management team to identify and execute on strategic venture investments that are closely aligned with AbbVie’s overall R&D and corporate strategy. Scott also serves as one of AbbVie’s primary spokespersons for R&D to global media, governmental officials, and institutional investors.
In his previous role, Scott was the head of Pharmaceutical Development at AbbVie, a global scientific and operational organization responsible for advancing a broad portfolio of early and late stage preregistrational pipeline compounds as well as marketed products within oncology, neurology, immunology, renal, infectious disease, and women’s and men’s health therapeutic areas.
Scott earned his bachelor’s degree in biochemistry from the University of Illinois at Urbana-Champaign. He earned his medical degree from The Johns Hopkins University School of Medicine and completed ophthalmology training at the Massachusetts Eye and Ear Infirmary/Harvard Medical School.
Shanghai Xingshi is a investment advisory firm. We mainly focus on US-listed biotech companies, covering therapeutic fields from oncology, gene therapies, to disease areas with significant unmet medical needs. We apply both fundamental analysis and event-driven approaches to provide investment guidance.
Focus on healthcare Biotech,Vice-President of KPC,Partner of Holley Assets.(SH:600422)
Terry Opgenorth, Ph.D., serves as VP and Executive Director of LAUNCHPAD for CSU Ventures. Dr. Opgenorth previously worked for Abbott Laboratories’ (now AbbVie) as Vice President of Metabolic Disease, Antiviral and Target-Lead Discovery Research for its Global Pharmaceutical Research and Development Division. He also served as President and CEO of Vidasym for 6 years, creating partnerships with companies in Japan and China to advance two drugs into clinical development for human chronic kidney disease. Terry holds a number of other positions, including CSO/Founder of VetDC, a veterinary oncology company, and Board Director KromaTiD, VetDC, UNeMed, MonImmune Therapeutics, Cetya Therapeutics, and PhotonPharma. He previously served as Founder/Advisor to Colorado Center for Drug Discovery (C2D2), and Board Director for Colorado Institute for Drug, Device, and Diagnostic Development (CID4), Colorado Bioscience Association, and Keystone Symposia. Dr. Opgenorth holds a B.A. in Biology from Calvin College and M.S. and Ph.D. degrees in Physiology from University of Illinois-Urbana.
Tim Xiao, B.Sc. FRM, is a Principal at Delos Capital since its inception in 2014 and has over 10 years¡¯ experience in investment banking and life sciences investment. Tim started his career as an investment banker at China International Capital, and later joined the Investment Banking Division of Goldman Sachs where he completed a series of industry-defining transactions with total deal value over US$4 billion. Tim serves as a Board member for Liposeuticals, Curatia Medical and as a Board Observer for Allecra Therapeutics, Intrinsic Therapeutics and Atia Vision.
Vcanbio Capital Management LLC is a VC fund focusing on biotech investment. We have invested into three startup companies founded by Harvard professors, and one founded by MIT professors.
VersaPeutics is a newly founded Biotech company aimed at developing therapies for repair and functional restoration of central nervous system after traumatic injury and novel treatment of brain tumor. We are preparing for raising A round funding.